Monitoring Blood Supply in Germany: A Regulatory Perspective.

Autor: Fiedler SA; Division Safety of Medicinal Products and Medical Devices, Paul-Ehrlich-Institut, Langen, Germany., Henseler O; Section of Transfusion Medicine, Paul-Ehrlich-Institut, Langen, Germany., Hoffelner M; Division Safety of Medicinal Products and Medical Devices, Paul-Ehrlich-Institut, Langen, Germany., Doll M; Section of Transfusion Medicine, Paul-Ehrlich-Institut, Langen, Germany., Hutschenreuter G; Institute of Transfusion Medicine, University Hospital, Rheinisch-Westfälische Technische Hochschule Aachen, Aachen, Germany., Hoch J; Institute of Experimental Haematology and Transfusion Medicine, University Clinic Bonn, Bonn, Germany., Weinauer F; German RC Blood Services, Working Group of the GRC, Berlin, Germany., Humpe A; Division of Transfusion Medicine, Cell Therapeutics and Haemostaseology University Hospital, LMU Munich, Munich, Germany., Funk MB; Division Safety of Medicinal Products and Medical Devices, Paul-Ehrlich-Institut, Langen, Germany., Hilger A; Section of Transfusion Medicine, Paul-Ehrlich-Institut, Langen, Germany.

Publikováno v: Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie [Transfus Med Hemother] 2023 Jan 18; Vol. 50 (2), pp. 129-134. Date of Electronic Publication: 2023 Jan 18 (Print Publication: 2023).

Population-Based Analysis of the Impact of Demographics on the Current and Future Blood Supply in the Saarland.

Autor: Eichler H; Universität des Saarlandes, Institut für Klinische Hämostaseologie und Transfusionsmedizin, Homburg, Germany., Feyer AK; Universität des Saarlandes, Institut für Klinische Hämostaseologie und Transfusionsmedizin, Homburg, Germany., Weitmann K; Universitätsmedizin Greifswald, Institut für Community Medicine, Greifswald, Germany., Hoffmann W; Universitätsmedizin Greifswald, Institut für Community Medicine, Greifswald, Germany., Henseler O; Paul-Ehrlich-Institut, Langen, Germany., Opitz A; DRK-Blutspendedienst Rheinland-Pfalz und Saarland, Bad Kreuznach, Germany., Patek A; Blutspendezentrale Saar-Pfalz, Klinikum Saarbrücken, Saarbrücken, Germany., Hans DN; Klinikum Merzig gGmbH, Merzig, Germany., Schönborn L; Universitätsmedizin Greifswald, Institut für Immunologie und Transfusionsmedizin, Greifswald, Germany., Greinacher A; Universitätsmedizin Greifswald, Institut für Immunologie und Transfusionsmedizin, Greifswald, Germany.

Publikováno v: Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie [Transfus Med Hemother] 2021 May; Vol. 48 (3), pp. 175-182. Date of Electronic Publication: 2020 Dec 23.

Effectiveness of blood donor screening by HIV, HCV, HBV-NAT assays, as well as HBsAg and anti-HBc immunoassays in Germany (2008-2015).

Autor: Fiedler SA; Safety of Medicinal Products and Medical Devices, Paul-Ehrlich-Institut, Langen, Germany., Oberle D; Safety of Medicinal Products and Medical Devices, Paul-Ehrlich-Institut, Langen, Germany., Chudy M; Testing Laboratory for in vitro diagnostic devices, Section of Molecular Virology, Paul-Ehrlich-Institut, Langen, Germany., Scheiblauer H; Testing Laboratory for in vitro diagnostic devices, Section of Molecular Virology, Paul-Ehrlich-Institut, Langen, Germany., Henseler O; Section of Transfusion Medicine, Paul-Ehrlich-Institut, Langen, Germany., Halbauer J; Safety of Medicinal Products and Medical Devices, Paul-Ehrlich-Institut, Langen, Germany., Heiden M; Safety of Medicinal Products and Medical Devices, Paul-Ehrlich-Institut, Langen, Germany., Funk M; Safety of Medicinal Products and Medical Devices, Paul-Ehrlich-Institut, Langen, Germany.

Publikováno v: Vox sanguinis [Vox Sang] 2019 Jul; Vol. 114 (5), pp. 443-450. Date of Electronic Publication: 2019 Apr 22.

A national surveillance system for continuous monitoring of blood transfusion safety: German haemovigilance data.

Autor: Berg P; Division Safety of Biomedicines and Diagnostics, Paul-Ehrlich-Institut (PEI), Langen, Germany., Heiden M; Division Safety of Biomedicines and Diagnostics, Paul-Ehrlich-Institut (PEI), Langen, Germany., Müller S; Division Safety of Biomedicines and Diagnostics, Paul-Ehrlich-Institut (PEI), Langen, Germany., Meyer B; Division Safety of Biomedicines and Diagnostics, Paul-Ehrlich-Institut (PEI), Langen, Germany., Witzenhausen C; Division Safety of Biomedicines and Diagnostics, Paul-Ehrlich-Institut (PEI), Langen, Germany., Ruppert-Seipp G; Division Safety of Biomedicines and Diagnostics, Paul-Ehrlich-Institut (PEI), Langen, Germany., Kehr S; Division Safety of Biomedicines and Diagnostics, Paul-Ehrlich-Institut (PEI), Langen, Germany., Funk MB; Division Safety of Biomedicines and Diagnostics, Paul-Ehrlich-Institut (PEI), Langen, Germany.

Publikováno v: Vox sanguinis [Vox Sang] 2024 Sep; Vol. 119 (9), pp. 953-962. Date of Electronic Publication: 2024 Jun 18.

Bericht zur Meldung nach § 21 TFG für die Jahre 2010 und 2011. (German)

Autor: Henseler, O., Heiden, M., Haschberger, B., Hesse, J., Seitz, R.

Publikováno v: Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz; Oct2013, Vol. 56 Issue 10, p1352-1367, 16p